160 related articles for article (PubMed ID: 34266853)
1. Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial).
Taylor S; Yorke J; Tsim S; Navani N; Baldwin D; Woolhouse I; Edwards J; Grundy S; Robson J; Rhodes S; Gomes F; Blackhall F; Faivre-Finn C; Evison M
BMJ Open Respir Res; 2021 Jul; 8(1):. PubMed ID: 34266853
[TBL] [Abstract][Full Text] [Related]
2. Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice.
Evison M; Edwards J; McDonald F; Popat S
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):527-536. PubMed ID: 32216979
[TBL] [Abstract][Full Text] [Related]
3. Study protocol for VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a UK multicentre randomised controlled trial with an internal pilot (the VIOLET study).
Lim E; Batchelor T; Shackcloth M; Dunning J; McGonigle N; Brush T; Dabner L; Harris R; Mckeon HE; Paramasivan S; Elliott D; Stokes EA; Wordsworth S; Blazeby J; Rogers CA;
BMJ Open; 2019 Oct; 9(10):e029507. PubMed ID: 31615795
[TBL] [Abstract][Full Text] [Related]
4. Surgery as a Component of Multimodality Care for Known Stage IIIA-N2 Non-small Cell Lung Cancer.
Bograd AJ; Vallières E
Semin Respir Crit Care Med; 2020 Jun; 41(3):346-353. PubMed ID: 32450588
[TBL] [Abstract][Full Text] [Related]
5. Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer.
Van Schil PE; Yogeswaran K; Hendriks JM; Lauwers P; Faivre-Finn C
Expert Rev Anticancer Ther; 2017 Jun; 17(6):555-561. PubMed ID: 28403675
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
7. MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial.
Bousema JE; Dijkgraaf MGW; Papen-Botterhuis NE; Schreurs HW; Maessen JG; van der Heijden EH; Steup WH; Braun J; Noyez VJJM; Hoeijmakers F; Beck N; van Dorp M; Claessens NJM; Hiddinga BI; Daniels JMA; Heineman DJ; Zandbergen HR; Verhagen AFTM; van Schil PE; Annema JT; van den Broek FJC;
BMC Surg; 2018 May; 18(1):27. PubMed ID: 29776444
[TBL] [Abstract][Full Text] [Related]
8. Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot.
Beard C; Rogers CA; Fleming L; Conibear J; Evison M; Newsom-Davis T; Barwick T; Mills N; Stokes EA; De Sousa P; Batchelor T; Rawlinson J; Baos S; Harris R; Lim E
BMJ Open; 2023 Dec; 13(12):e081650. PubMed ID: 38072470
[TBL] [Abstract][Full Text] [Related]
9. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection.
Snee MP; McParland L; Collinson F; Lowe CM; Striha A; Baldwin DR; Naidu B; Sebag-Montefiore D; Gregory WM; Bestall J; Hewison J; Hinsley S; Franks K
Pilot Feasibility Stud; 2016; 2():5. PubMed ID: 27965826
[TBL] [Abstract][Full Text] [Related]
10. Resectable Clinical N2 Non-Small Cell Lung Cancer; What Is the Optimal Treatment Strategy? An Update by the British Thoracic Society Lung Cancer Specialist Advisory Group.
Evison M; Clive A; Castle L; Powell H; Thomas R; Buttery R; Masani V; Harden S; West D; Woolhouse I
J Thorac Oncol; 2017 Sep; 12(9):1434-1441. PubMed ID: 28624466
[TBL] [Abstract][Full Text] [Related]
11. Role of surgery in N2 NSCLC: pros.
Shien K; Toyooka S
Jpn J Clin Oncol; 2016 Dec; 46(12):1168-1173. PubMed ID: 27655902
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
Tieu BH; Sanborn RE; Thomas CR
Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
[TBL] [Abstract][Full Text] [Related]
13. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.
Bendixen M; Jørgensen OD; Kronborg C; Andersen C; Licht PB
Lancet Oncol; 2016 Jun; 17(6):836-844. PubMed ID: 27160473
[TBL] [Abstract][Full Text] [Related]
14. Non-small-cell lung cancer: multimodality approach in stage-III resectable disease.
Thomas M; Hoffknecht P; Droege C; Baisch A; Reinmuth N; Kreuter M; Lange T; Berdel WE
Lung Cancer; 2004 Aug; 45 Suppl 2():S99-105. PubMed ID: 15552789
[TBL] [Abstract][Full Text] [Related]
15. Should surgery be part of the multimodality treatment for stage IIIB non-small cell lung cancer?
Collaud S; Provost B; Besse B; Fabre D; Le Chevalier T; Mercier O; Mussot S; Fadel E
J Surg Oncol; 2018 Jun; 117(7):1570-1574. PubMed ID: 29573419
[TBL] [Abstract][Full Text] [Related]
16. Multimodality treatment with surgery for locally advanced non-small-cell lung cancer with n2 disease: a review article.
Toyokawa G; Takenoyama M; Ichinose Y
Clin Lung Cancer; 2015 Jan; 16(1):6-14. PubMed ID: 25220209
[TBL] [Abstract][Full Text] [Related]
17. Is surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement?
Bakir M; Fraser S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Sep; 13(3):303-10. PubMed ID: 21685220
[TBL] [Abstract][Full Text] [Related]
18. Carer administration of as-needed subcutaneous medication for breakthrough symptoms in people dying at home: the CARiAD feasibility RCT.
Poolman M; Roberts J; Wright S; Hendry A; Goulden N; Holmes EA; Byrne A; Perkins P; Hoare Z; Nelson A; Hiscock J; Hughes D; O'Connor J; Foster B; Reymond L; Healy S; Lewis P; Wee B; Johnstone R; Roberts R; Parkinson A; Roberts S; Wilkinson C
Health Technol Assess; 2020 May; 24(25):1-150. PubMed ID: 32484432
[TBL] [Abstract][Full Text] [Related]
19. Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small-cell lung cancer: a systematic review.
Swaminath A; Vella ET; Ramchandar K; Robinson A; Simone C; Sun A; Ung YC; Yasufuku K; Ellis PM
Curr Oncol; 2019 Jun; 26(3):e398-e404. PubMed ID: 31285684
[TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic ultrasound relative to surgical staging in potentially resectable lung cancer: results from the ASTER randomised controlled trial.
Sharples LD; Jackson C; Wheaton E; Griffith G; Annema JT; Dooms C; Tournoy KG; Deschepper E; Hughes V; Magee L; Buxton M; Rintoul RC
Health Technol Assess; 2012; 16(18):1-75, iii-iv. PubMed ID: 22472180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
